Evaluation of immunological response following a revaccination with PPS23 boosted or not by PCV13 in splenectomised patients (SPLENEVAC-2)
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms SPLENEVAC-2
- 27 Aug 2019 Planned End Date changed from 1 Oct 2023 to 1 Aug 2023.
- 27 Aug 2019 Planned primary completion date changed from 1 Apr 2023 to 1 Sep 2022.
- 27 Aug 2019 Status changed from not yet recruiting to recruiting.